Overview

The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The Safety and Tolerability of COMP360 in Participants with Post-traumatic Stress Disorder
Phase:
Phase 2
Details
Lead Sponsor:
COMPASS Pathways
Treatments:
Psilocybin